The Company has acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP on a slump sale basis pursuant to the BTA Agreement as on 30.06.2025. Accordingly the LLP has ceased the business operations and is in the process of winding up under the LLP Act 2008. Consequently the Company does not have any subsidiary, associate or joint venture as on 30.09.2025 and therefore no consolidated financial results are required to be presented from this quarter onwards.

pdf

Aspira Pathlab & Diagnostics Ltd.

12 Nov 2025

61.38

-1.00%

Board Meeting

Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Outcome for Outcome Of Board Meeting …

BSE India

Outcome of Board Meeting held on November 12, 2025

pdf

Aspira Pathlab & Diagnostics Ltd.

04 Nov 2025

61.38

-1.00%

Board Meeting

Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation for The Board Meeting To …

BSE India

Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results alongwith the Limited Review Report as on September 30, 2025.

pdf

Aspira Pathlab & Diagnostics Ltd.

13 Oct 2025, 07:27PM

61.38

-1.00%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Open Offer - Updates

BSE India

Announcement as per Reg 30-Letter of Offer

pdf

Aspira Pathlab & Diagnostics Ltd.

13 Oct 2025, 06:43PM

61.38

-1.00%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Draft Letter of Offer

BSE India

Aftertrade Broking Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer to the Public Shareholders of Aspira Pathlab & Diagnostics Ltd ("Target Company").

pdf

Aspira Pathlab & Diagnostics Ltd.

07 Oct 2025

61.38

-1.00%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) …

BSE India

Compliance Certificate under reg 74 (5) of SEBI (DP) regulation, 2018 for the quarter ended September 30, 2025

pdf

Aspira Pathlab & Diagnostics Ltd.

06 Oct 2025

61.38

-1.00%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosure Regarding Detailed Public Statement ("DPS") In Relation …

BSE India

Disclosure regarding Detailed Public Statement ("DPS") in relation to the Open Offer to the Public Shareholders

pdf

Aspira Pathlab & Diagnostics Ltd.

06 Oct 2025

61.38

-1.00%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Detailed Public Statement

BSE India

Aftertrade Broking Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Detailed Public Statement in terms of Regulations 13(4), 14(3) and 15(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and subsequent amendments thereof ("SEBI (SAST) Regulations, 2011,") for the attention of the Public Shareholders of Aspira Pathlab & Diagnostics Ltd ("Target Company").

pdf

Is Aspira Pathlab & Diagnostics Ltd. worth buying?

4 Votes:

Buy 25.0%

Sell 50.0%

Hold 25.0%

42.52% Fall from 52W High

High volume today

Aspira Pathlab & Diagnostics Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Aspira Pathlab & Diagnostics Ltd. on BSE